CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 80 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $587,866 | -24.1% | 32,623 | -32.4% | 0.27% | -57.4% |
| Q1 2023 | $774,815 | -54.9% | 48,245 | -48.6% | 0.63% | -38.1% |
| Q4 2022 | $1,718,242 | -5.0% | 93,893 | +2.0% | 1.02% | -1.3% |
| Q3 2022 | $1,808,000 | +194.5% | 92,047 | +179.4% | 1.03% | +178.4% |
| Q2 2022 | $614,000 | -36.8% | 32,948 | -25.5% | 0.37% | -39.9% |
| Q1 2022 | $971,000 | -35.5% | 44,226 | -16.5% | 0.62% | -48.5% |
| Q4 2021 | $1,505,000 | +211.6% | 52,982 | +71.8% | 1.20% | +240.3% |
| Q3 2020 | $483,000 | +7.3% | 30,845 | +20.0% | 0.35% | -5.6% |
| Q2 2020 | $450,000 | – | 25,701 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |